Table 7.

Detection of bacterial virulence factors and platelet activation markers on platelets from HUS patients by immunofluorescence

	Patient and strain characteristics			Markers on platelets
Patient no.	Diagnosis	E coli serotype*	Fecal stx type†	O157LPS	Stx1	Stx2	CD62	Fibrinogen
1	HUS	O157	stx2	+	+	−	−	+
2	HUS	O157§	stx2	+	+	−	−	+
3	HUS	O157∥	stx2	+	+	+	NA	+
4	HUS	O157∥	stx2	+	+	−	NA	−
5	HUS	O157	stx2	−	−	−	+	+
6	HC‡	O157∥	stx2	+	−	+	−	+
7	HUS	O111¶	NA	−	+	−	+	+
8	HUS	O157¶	NA	+	+	−	−	−
9	HUS	O157¶	NA	+	NA	NA	−	+
10	HUS	O157	stx2	+	+	+	−	+
11	HUS	O157∥	stx2	+	+	+	−	+
12	HUS	O157∥¶	NA	+	+	+	−	+
13	HUS	O157¶	NA	+	+	+	−	+
14	HUS	O157	stx2	−	−	+	−	+
15	Pre-HUS	O157	stx1,stx2	+	+	−	+	−
16	Pre-HUS	O157	stx2	+	+	−	+	+
16	HUS	O157	stx2	+	+	−	−	+

Patients 1-14 were treated at the Department of Pediatrics, Lund, Sweden; patients 15 and 16, at CHRMC, Seattle, WA.

NA indicates not available; HC, hemorrhagic colitis.

^*E. coli serotype was determined by serotyping of a fecal isolate or by serum antibodies to specific LPS serotypes.²⁶

^†Fecal Shiga toxin type was determined by PCR.

^‡Incomplete HUS.

^§Fecal PCR²⁷ results were positive for stx and eae, but a bacterial strain was not isolated. E. coli serotype was determined by ELISA detection of anti-O157LPS.

^∥LPS was not detected on the platelets of these patients after recovery.

^¶Feces were unavailable or fecal PCR was negative, and the E. coli serotype was determined by ELISA for the detection of anti-LPS.